Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
LXRX

LEXICON PHARMACEUTICALS (LXRX) stock: insider trades, news & valuation

Net buying
Close · Oct 9, 2026 $1.68 -4.5% on the day +2.4% over 12 months 52-week range $1.14 – $2.64

Share price and insider trades

LXRX closeInsider buyInsider sale
1.001.502.002.503.00NovDecJan 2026FebMarAprMayJunJulAugSepOctBought $2,980 on 2026-02-25 · Raymond DebbaneBought $72,000 on 2026-02-19 · Raymond DebbaneBought $75,917 on 2026-02-13 · Raymond DebbaneBought $100,683 on 2026-02-17 · Raymond DebbaneBought $147,000 on 2026-02-23 · Raymond DebbaneBought $148,000 on 2026-02-20 · Raymond DebbaneBought $176,468 on 2026-02-18 · Raymond DebbaneBought $2,000,001 on 2026-02-02 · Group S.a. Artal
Bought, 12 months$2.7M
Sold, 12 months$0
Insiders buying2
Insiders selling0

LEXICON PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $2.7M and 0 sold $0 of LXRX stock on the open market.

LXRX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q1 2026: $2.7M bought (8 trades)$2.7MQ1 2026Q2 2026Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0—0
Q2 2026—0—0
Q1 2026$2.7M8—0

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit+$736KOn all tracked purchases +27.0%

Summary

Over the past 12 months, 2 LEXICON PHARMACEUTICALS, INC. insiders reported open-market purchases totaling $2.7M, while 0 insiders reported sales totaling $0. Among insiders with enough purchase history to measure, Raymond Debbane (Director) has the highest Insider Score at 95.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Feb 27SEC Raymond DebbaneDirector Buy 2,0001,906,186 held (+0%) $1.49 $3K +12.8% 95
Feb 25SEC Raymond DebbaneDirector Buy 100,0001,904,186 held (+6%) $1.47 $147K +14.3% 95
Feb 23SEC Raymond DebbaneDirector Buy 100,0001,804,186 held (+6%) $1.48 $148K +13.5% 95
Feb 23SEC Raymond DebbaneDirector Buy 50,0001,704,186 held (+3%) $1.44 $72K +16.7% 95
Feb 18SEC Raymond DebbaneDirector Buy 133,6881,654,186 held (+9%) $1.32 $176K +27.3% 95
Feb 18SEC Raymond DebbaneDirector Buy 76,8571,520,498 held (+5%) $1.31 $101K +28.2% 95
Feb 18SEC Raymond DebbaneDirector Buy 57,9521,443,641 held (+4%) $1.31 $76K +28.2% 95
Feb 4SEC Group S.a. ArtalDirector Buy 1,538,462new position $1.30 $2.0M +29.2% —

Insiders at LEXICON PHARMACEUTICALS, INC.

InsiderBoughtSoldLast filingScore
Group S.a. ArtalDirector $2.0M — Feb 4, 2026 —
Raymond DebbaneDirector $723K — Feb 27, 2026 95

LXRX stock: common questions

Are LEXICON PHARMACEUTICALS, INC. insiders buying LXRX stock?

In the past 12 months, 2 insiders reported open-market purchases of LXRX worth $2.7M. The latest was Director Raymond Debbane bought $3K of LXRX at $1.49.

Are LEXICON PHARMACEUTICALS, INC. insiders selling LXRX stock?

0 insiders reported sales worth $0 over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is LXRX's 52-week range?

Over the past year LXRX has traded between $1.14 and $2.64. It last closed at $1.68 on Oct 9, 2026.